Novo Nordisk's CagriSema delivers 21% weight loss at 68 weeks in obesity trial
NVO•Novo Nordisk reported that CagriSema produced 21% weight loss at 68 weeks in an obesity trial and outperformed tirzepatide in adults with diabetes and obesity. In the REIMAGINE 5 trial, it was non-inferior to tirzepatide in reducing blood sugar.
1. Trial results
Novo Nordisk reported results from the REIMAGINE 5 trial on November 4, 2026, showing CagriSema delivered 21% weight loss at 68 weeks and greater weight loss than tirzepatide in adults with diabetes and obesity. CagriSema was non-inferior to tirzepatide in reducing blood sugar.
